Training
	1968	B.A., University of California, Berkley, Bacteriology and Immunology
	1976	Ph.D., University of California, Berkley, Immunology
	1976	Postdoctoral Fellow, Immunology Department of Pathology, Univ. of Pennsylvania School of Medicine
	1976-1979	Postdoctoral Fellow Immunology / Oncology, Department of Medicine, Division of Oncology, Stanford University School of Medicine
Academic Appointments
	1979-1986	Assistant Professor of Anatomy , University of Pennsylvania School of Medicine
	1986-1987	Visiting Scientist, Children's Cancer Research Center, Children's Hospital of Philadelphia
	1986-1987	Adjunct Associate Professor of Neurology, University of Pennsylvania School of Medicine
	1987-1990	Assistant Professor of Neuroscience in the Department of  Neurology, Harvard Medical School
	1987-1990	Associate Immunologist, Brigham and Women's Hospital, Boston
	1990-	Associate Professor of Neurology, Harvard Medical School
	1990-	Immunologist, Brigham and Women's Hospital, Boston
	1998-	Biology Concentration Affiliates Program, Faculty of Arts and Science Harvard University
	1999-	Associate Professor of Neurosurgery, Harvard Medical School
	1999-	Member, Dana-Farber/Harvard Cancer Center

 Advisory and editorial boards (current and representative)

1990-95             Founding editorial board,Brain Pathology (International Society of Neuropathology)

1993-98             Advisory Committee on Fellowships, National Multiple Sclerosis Society (NMSS)

1993                 Neuroimmunology and Mental Health Advisory Panel, NIMH

1994-                Medical Advisory Council, American Brain Tumor Association (ABTA)

1995                 Special emphasis panel ZMH1-NRB-R-0-2 (BBB in HIV), NIMH

1996                 Study section, Mental Health, AIDS and Immunology study section (NIMH/MHAI-2)

1997-01             Editorial board, JNEN (Journal of Neuropathology and Experimental Neurology)

1998-                Editorial board, JNO (Journal of Neuro-Oncology), first board under new leadership

1998-                Study section, Neurological Sciences and Disorders Review Subcommittee B (NINDS/NSDB)

1999                 Scientific Advisory Board, 13th Int Conf on Brain Tumor Research and Therapy, 1999, Sapporo, Japan

Selected publications

1. Lampson LA, Levy R, Grumet FC, Ness D, Pious D. Production in vitro of murine antibody to a human histocompatibility alloantigen. Nature 271: 461-462, 1978.

2. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line. J. Immunol. 125: 293-99, 1980.

3. Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A,B,C and b2-microglobulin on human neuroblastoma cell lines. J. Immunol. 130: 2471-8, 1983.

4. Lampson LA, Fisher CA. Weak HLA and b2-m expression of neuronal cell lines can be modulated by interferon. PNAS 81: 6476-80, 1984.

5. Whelan JP, Chatten J, Lampson LA. HLA-A,B,C and b2-microglobulin expression on frozen, and formaldehyde-fixed paraffin sections of neuroblastoma tumors. Cancer Res. 45: 5976-83, 1985.

6. Main EK, Lampson LA, Hart MK, Kornbluth J, Wilson DB. Human neuroblastoma cell lines are susceptible to lysis by NK cells but not by CTL. J. Immunol. 135: 242-46, 1985.

7. Lampson LA, Hickey WF. Monoclonal antibody analysis of MHC expression in human brain biopsies: Tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J. Immunol. 136: 4054-62, 1986.

8. Lampson L. Molecular bases of immune response to neural antigens. TINS 10: 211-16, 1987.

9. Main EK, Monos DS, Lampson LA. IFN-treated neuroblastoma cell lines remain resistant to T cell allokilling and susceptible to non-MHC-restricted cytotoxicity. J. Immunol. 141: 2943-50, 1988.

10. Turner WJD, Chatten J, Lampson LA. Human neuroblastoma cell growth in xenogeneic hosts: Comparison of T cell-- and NK-- hosts, and s.c. or i.v. injection routes. J. Neuro-Oncol. 8: 121-32, 1990.

11. Lampson LA. MHC regulation in neural cells: Distribution of peripheral and internal b2-m and class I molecules in human neuroblastoma cell lines. J. Immunol. 144: 512-20, 1990.

12. Lampson LA, Kushner PD, Sobel RA. Major histocompatibility antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann. Neurol. 28: 365-72, 1990.

13. Wen P, Loeffler JS, Morris JH, Lampson LA. Effects of irradiation on MHC expression and lymphocyte infiltration in normal brain and 9L brain tumor model. J. Neuroimm. 27: 239-44, 1990.

14. Sethna MP, Lampson LA. Recruitment of inflammatory cells and increased MHC antigen expression following intracerebral injection of IFN-g. J. Neuroimm. 34: 121-32, 1991.

15. Lampson LA, Wen P, Roman VA, Morris JH, Sarid J. Disseminating tumor cells and their interactions with leukocytes visualized in the brain. Cancer Res. 52: 1008-25, 1992.

16. Wen P, Lampson MA, Lampson LA. Effects of IFN-g on MHC expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model. J. Neuroimm. 36: 57-68, 1992.

17. Lampson LA, Lampson MA, Dunne AD. Exploiting lacZ reporter gene for quantitative analysis of disseminated tumor growth in the brain: Use of lacZ gene product as tumor antigen, to evaluate antigenic modulation, and to facilitate image analysis. Cancer Res. 53: 176-82, 1993.

18. Drew P, Lonegren M, Goldstein M, Lampson L, Ozato K, McFarlin D. Regulation of MHC I and b2-m gene expression in human neuronal cells. Factor binding activity to conserved cis-acting regulatory sequences correlates with expression of the genes. J. Immunol. 150: 3300-10, 1993.

19. Lehky T, Cowan E, Lampson L, Jacobson S. Induction of HLA class I and class II expression in human T-lymphotropic virus type 1-infected neuroblastoma cells. J. Virol. 68: 1854-63, 1994.

20. Lampson LA, Chen A, Vortmeyer AO, Sloan AE, Ghogawala Z, Kim L. Enhanced T cell migration to sites of microscopic CNS disease: Complementary treatments evaluated by 2- and 3-D image analysis. Brain Pathol. 4: 125-34, 1994.

21. Lampson LA. Interpreting MHC class I expression and class I/class II reciprocity in the CNS: Reconciling divergent findings. Micros Res Tech 32: 267-285, 1995.

22. Grabowska A, Lampson LA. MHC expression in nonlymphoid tissues of the developing embryo: Strongest class I or II expression in separate populations of potential APC in skin, lung, gut, and inter-organ connective tissue. Dev. Comp. Immunol. 19: 425-450, 1995.

23. Armstrong, WS and Lampson, LA. Direct cell-mediated responses in the nervous system: CTL vs. NK activity, and their dependence upon MHC expression and modulation. In: Immunology of the Nervous System, R.W. Keane and W.F. Hickey, eds., Oxford, 1997, pp. 493-547.

24. Lampson LA. Immunobiology of brain tumors: Antigens, effectors, and delivery to sites of microscopic tumor in the brain. Black P, Loeffler J, eds., 1997, Cancer of the Nervous System, Blackwell, pp. 874-906.

25. Lampson LA. Beyond Inflammation: Site-directed Immunotherapy. Immunol. Today, 1998, 19: 17-22. 

26. Phillips LM, Simon P, Lampson LA. Site-specific immune regulation in the brain: differential modulation of MHC proteins in brainstem vs. hippocampus. J. Comp. Neurol., 405: 322-333, 1999.

27. Phillips LM, Lampson LA. Site-specific control of T cell traffic in the brain: T cell entry to brain stem vs. hippocampus after local injection of IFN-g. J. Neuroimmunol. 96: 218-227, 1999. 

28. McCluskey, LP and Lampson, LA. Local neurochemicals and site-specific immune regulation in the CNS. (Invited review.) JNEN 2000, 59: 177-187.

29. McCluskey LP, Lampson LA: Local immune regulation in the central nervous system by substance P vs. glutamate. J Neuroimmunol 2001, 116: 136-146. 

30. Lampson LA: New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns J Neuro-Oncol 2001, 53: 275-287.

31. Lampson LA: Basic Principles of CNS immunology. In Winn, HR, ed., Youman's Neurological Surgery, 5th edition, WB Saunders, 2002, in press.

32. Lampson LA: Principles of immune regulation in the CNS. Human Brain Tumors. F. Ali-Osman ed, Humana 2002, in press.

Abstracts (selected)

33. Dutta T, Spence A, Lampson LA, Defining the limits of brain -enhanced MHC expression in tumor-bearinggtumor-mediated immunosuppression: IFN- brains. Presented at AACR Ann Mtg, 1998, poster-disc.

34. Kondo Y, Lampson LA. Enhancing T cell surveillance of brain micro-tumor: Different drugs optimize T cell entry to grey or white matter. Cancer Res 2000: 41, 192, abstract #1226.

35. Seabrook TS, Lampson LA. IFN-g increases the entry of T cells at micro-tumors in a rat model of brainstem glioma. AAI Annual Meeting, 2002, in press.

36. McCluskey LP, Lampson LA, Substance P (SP) Amplifies ability of gamma interferon (IFN-g) to increase T cell entry to brainstem, AAN Annual Meeting, 2002, in press.

Books & edited work.

37. Black P, Schoene W, Lampson L eds, Astrocytomas: Blackwell 1993.

38. Lampson LA ed, Mechanisms and control of cell migration in the adult CNS. Brain Pathol 4, 1994.

39. Lampson LA ed, Animal models of CNS tumor. J Neuro-Oncol 2001, 53: 275-318. 

Meetings and classes organized (selected). Lampson LA, initiator and chair for each:

Gordon Research Conference on Biology of the immune response to antigen within the CNS, 1993.

Brain Tumor Research Day, Harvard Medical School, 1995.

Harvard Neurology Research Symposia, Harvard Medical School, 1994, 1996.

Signal bigamy in the brain, workshop, WCBR, 1998.

Multi-functional neurochemicals, Course, Neurobiology 300, HMS, 2001.

Reagents made available through ATCC: Monoclonals to human MHC (L203, L227, L243, L368); visualizable brain tumor cell lines (9L/lacZ; C6/lacZ; C6/LACZ7).